Abstract
Sushi repeat-containing protein X-linked 2 (SRPX2) is a novel chondroitin sulfate proteoglycan overexpressed in gastrointestinal cancer. Its role in tumor biology remains unknown. The aim of this study was to investigate the expression of SRPX2 in colorectal cancer and its potential association with cancer progression. The expression of SRPX2 and its clinicopathological significance was evaluated using immunohistochemistry in a tissue microarray including 88 colon cancer and pairing normal tissues. The impact of SRPX2 on behavior of colorectal cancer cells and possible mechanism was explored using gene transfection and silencing. Strong staining of SRPX2 was noted in 71 (80.7 %) of 88 colon cancer specimen and 30 (34.1 %) of 88 adjacent normal tissues (P < 0.001). The expression of SRPX2 was significantly correlated with histological differentiation grade (P = 0.003), infiltration depth (P = 0.003), and clinical stage (P = 0.006). The expression of SRPX2 was significantly higher in HCT116 than in HT29 and SW480 cells. Suppression of endogenous SRPX2 expression by small interfering ribonucleic acid (siRNA) in HCT116 cells resulted in significant reduction in the ability of cell proliferation, adhesion, migration, and invasion. Up-regulation of endogenous SRPX2 in SW480 cells significantly promoted the migration and invasion of SW480 cells. In addition, inhibition of SRPX2 by siRNA led to notable down-regulation of β-catenin, matrix metalloproteinase (MMP)-2, and MMP-9. These findings indicate that overexpressed SRPX2 exerts an oncogenic role in colorectal cancer. SRPX2 may promote the invasion of colorectal cancer through MMP-2 and MMP-9 modulated by Wnt/β-catenin pathway.
Similar content being viewed by others
References
Brenner H, Kloor M, Pox CP. Colorectal cancer. Lancet. 2014;383(9927):1490–502.
Lu PF, Weaver VM, Werb Z, et al. The extracellular matrix: a dynamic niche in cancer progression. JCB. 2012;196(4):395–406.
Ricciardelli C, Mayne K, Sykes PJ, et al. Elevated stromal chondroitin sulfate glycosaminoglycan predicts progression in early-stage prostate cancer. Clin Cancer Res. 1997;3(6):983–92.
Pothacharoen P, Siriaunkgul S, Ong-Chai S, et al. Raised serum chondroitin sulfate epitope level in ovarian epithelial cancer. J Biochem. 2006;140(4):517–24.
Olsen EB, Trier K, Eldov K, et al. Glycosaminoglycans in human breast cancer. Acta Obstet Gynecol Scand. 1988;67(6):539–42.
Iida J, Wilhelmson K, Ng J, et al. Cell surface chondroitin sulfate glycosaminoglycan in melanoma: role in the activation of pro-MMP-2 (pro-gelatinase A). Biochem J. 2007;403:553–63.
Dwyer CA, Bi WL, Viapiano MS, et al. Brevican knockdown reduces late-stage glioma tumor aggressiveness. J Neurooncol. 2014;120(1):63–72.
Basappa, Murugan S, Sugahara KN, et al. Involvement of chondroitin sulfate E in the liver tumor focal formation of murine osteosarcoma cells. Glycobiology. 2009;19(7):735–42.
Jia XL, Li SY, Dang SS, et al. Increased expression of chondroitin sulphate proteoglycans in rat hepatocellular carcinoma tissues. World J Gastroenterol. 2012;18(30):3962.
de Wit M, Belt EJ, Delis-van Diemen PM, et al. Lumican and versican are associated with good outcome in stage II and III colon cancer. Ann Surg Oncol. 2013;20(Suppl 3):S348–59.
Mukaratirwa S, Van Ederen AM, Gruys E, et al. Versican and hyaluronan expression in canine colonic adenomas and carcinomas: relation to malignancy and depth of tumour invasion. J Comp Pathol. 2004;131(4):259–70.
Yang W, Yee AJ. Versican V2 isoform enhances angiogenesis by regulating endothelial cell activities and fibronectin expression. FEBS Lett. 2013;587(2):185–92.
Du WW, Fang L, Yang X, et al. The role of versican in modulating breast cancer cell self-renewal. Mol Cancer Res. 2013;11(5):443–55.
Kurosawa H, Goi K, Inukai T, et al. Two candidate downstream target genes for E2A-HLF. Blood. 1999;93(1):321–32.
Tanaka K, Arao T, Tamura D, et al. SRPX2 is a novel chondroitin sulfate proteoglycan that is overexpressed in gastrointestinal cancer. PLoS One. 2012;7(1):e27922.
Tanaka K, Arao T, Maegawa M, et al. SRPX2 is overexpressed in gastric cancer and promotes cellular migration and adhesion. Int J Cancer. 2009;124(5):1072–80.
Yamada T, Oshima T, Yoshihara K, et al. Impact of overexpression of Sushi repeat-containing protein X-linked 2 gene on outcomes of gastric cancer. J Surg Oncol. 2014;109(8):836–40.
Øster B, Linnet L, Christensen LL, et al. Non-CpG island promoter hypomethylation and miR-149 regulate the expression of SRPX2 in colorectal cancer. Int J Cancer. 2013;132(10):2303–15.
Liu KL, Zhou Y, Wu J. Construction of a eukaryotic vector expressing SRPX2 and its expression in cell line SW480. Shijie Huaren Xiaohua Zazhi. 2014;22(18):2553–8. doi:10.11569/wcjd.v22.i18.2553 (A Chinese Journal).
Royer-Zemmour B, Ponsole-Lenfant M, Gara H, et al. Epileptic and developmental disorders of the speech cortex: ligand/receptor interaction of wild-type and mutant SRPX2 with the plasminogen activator receptor uPAR. Hum Mol Genet. 2008;17(23):3617–30.
Miljkovic-Licina M, Hammel P, Garrido-Urbani S, et al. Sushi repeat protein X-linked 2, a novel mediator of angiogenesis. FASEB J. 2009;23(12):4105–16.
Ishiwata T, Fujii T, Ishiwata S, et al. Effect of morpholino antisense oligonucleotide against lumican mRNA in human embryonic kidney (HEK) 293 cells. Pathol Int. 2004;54(2):77–81.
Nikitovic D, Berdiaki A, Zafiropoulos A, et al. Lumican expression is positively correlated with the differentiation and negatively with the growth of human osteosarcoma cells. FEBS J. 2008;275(2):350–61.
Yamamoto T, Matsuda Y, Kawahara K, et al. Secreted 70 kDa lumican stimulates growth and inhibits invasion of human pancreatic cancer. Cancer Lett. 2012;320(1):31–9.
Vuillermoz B, Khoruzhenko A, D’Onofrio MF, et al. The small leucine-rich proteoglycan lumican inhibits melanoma progression. Exp Cell Res. 2004;296(2):294–306.
Theocharis AD, Gialeli C, Bouris P, et al. Cell–matrix interactions: focus on proteoglycan–proteinase interplay and pharmacological targeting in cancer. FEBS J. 2014;281(22):5023–42.
Kessenbrock K, Plaks V, Werb Z. Matrix metalloproteinases: regulators of the tumor microenvironment. Cell. 2010;141(1):52–67.
Bhattacharyya S, Feferman L, Tobacman JK. Increased expression of colonic Wnt9A through Sp1-mediated transcriptional effects involving arylsulfatase B, chondroitin-4-sulfate, and galectin-3. J Biol Chem. 2014: jbc. M114. 561589.
Willis CM, Klüppel M. Chondroitin sulfate-E is a negative regulator of a pro-tumorigenic Wnt/beta-catenin-collagen 1 axis in breast cancer cells. PLoS One. 2014;9(8):e103966.
Qu B, Liu BR, Du YJ, et al. Wnt/β-catenin signaling pathway may regulate the expression of angiogenic growth factors in hepatocellular carcinoma. Oncol Lett. 2014;7(4):1175–8.
Acknowledgments
Authors received support from Beijing Natural Science Foundation, No. 7133239 and Senior Talents Training Program of Beijing Health Care System, No. 2011-RC1.
Conflict of interest
None.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Liu, K.L., Wu, J., Zhou, Y. et al. Increased Sushi repeat-containing protein X-linked 2 is associated with progression of colorectal cancer. Med Oncol 32, 99 (2015). https://doi.org/10.1007/s12032-015-0548-4
Received:
Accepted:
Published:
DOI: https://doi.org/10.1007/s12032-015-0548-4